Nature Sub-journal: 2020 Biopharmaceutical Market of the Year

In 2020, many industries will be affected by the outbreak.
face of the epidemic, all parties in the pharmaceutical industry are united to meet the challenges.
is committed to the development of therapeutic drugs and vaccines by pooling resources and data sharing, which has undoubtedly brought about changes in the pharmaceutical industry, including a very important trading market.
Recently, Nature Reviews Drug Discovery published an article on Biopharma dealmaking in 2020, reviewing the trading market in the biopharmaceutical industry in 2020.
2020, there will be 166 mergers and acquisitions in the biopharmaceutical sector, with a total value of $131 billion.
the first half of the year was not very active because of the outbreak, with total transactions in the first and second quarters amounting to between $6 billion and $7 billion.
the third and fourth quarters of this year saw big increases, with total transactions reaching $43 billion and $74 billion, respectively.
of the top 10 M.A. deals, all but one occurred in the second half of 2020.
December, AstraZeneca announced a $39bn acquisition of Alexion Pharmaceuticals, making it the largest M.A. deal of 2020.
September, Gilead Sciences announced a $21bn acquisition of Immunomedics as the second-largest deal.
number one deal is nearly twice as high as the number two.
immunology remains at the top of the M.A. market in 2020, with three of the top 10 deals related to it: in addition to AstraZeneta's acquisition of Alexion Pharmaceuticals, which expanded the development of drugs in immunology, in August, Johnson and Johnson Johnson announced a $6.5 billion acquisition of Momenta, and Sanofi announced a $3.68 billion acquisition of Principia Biopharma, acquiring three of Principia's Tyrosine Kinase (BTK) inhibitors.
's top 10 deals for total M.A. deals in 2020 (Pharmaceutical Mingkang Content Team Translation, Source: References) Gilead continues to expand its reach in the oncology sector, acquiring Forty Seven for $4.9 billion and Immunomedics for $21 billion, respectively.
Forty Seven's main research and development project is an anti-CD47 monoclonal antibody called 5F9 (magrolimab), while Immunomedics sells the "first-in-class" antibody concatenated drug Trodelvy, which targets Trout-2, to Gilead.
accounts for 30 percent of more than $1 billion in mergers and acquisitions by 2020.
between biopharmaceutical companies will also grow steadily in 2020, with 1,153 collaborations announced despite the outbreak (with a total valuation of $183 billion).
of the top 10 in the U.S. and China reached $42 billion, or nearly 25 percent of the total.
of these collaborations occurred in the second quarter of 2020.
oncology also dominates the cooperative trade, with seven of the top 10 collaborations centered on cancer collaborations.
, infectious diseases and neurological diseases accounted for the top three in terms of cooperation, accounting for 32%, 24% and 14% of the total number of cooperation, respectively.
's top 10 deals in total cooperative transactions in 2020 (Pharmaceutical Mingkang content team translation, data source: reference: reference) are well known, the particularity of biopharmaceutical research and development investment, which determines that its research and development strategy needs to be matched with moderate mergers and acquisitions and extensive cooperation.
the positive promotion of many excellent policies and the continuous breakthrough of biotechnology, the biopharmaceutical market has gained more capital favor.
we look forward to the new year.
and most looking forward to, pharmaceutical companies can be in the changing pharmaceutical situation, for patients around the world to bring more treatment options! References: Biopharma dealmaking in 2020. Retrieved Jan 19 2021, from